Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection

Data are limited on the risk of de novo hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) after achieving sustained virologic response (SVR